Fennec Pharmaceuticals Inc. (FENC) EPS Estimated At $-0.10

July 14, 2018 - By Richard Slagle

Analysts expect Fennec Pharmaceuticals Inc. (NASDAQ:FENC) to report $-0.10 EPS on August, 10.They anticipate $0.01 EPS change or 9.09 % from last quarter’s $-0.11 EPS. After having $-0.09 EPS previously, Fennec Pharmaceuticals Inc.’s analysts see 11.11 % EPS growth. The stock decreased 1.33% or $0.13 during the last trading session, reaching $9.68. About 29,102 shares traded. Fennec Pharmaceuticals Inc. (NASDAQ:FENC) has risen 191.86% since July 14, 2017 and is uptrending. It has outperformed by 179.29% the S&P500.

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. The company has market cap of $179.84 million. The Company’s lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. It currently has negative earnings. The firm was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.

Another recent and important Fennec Pharmaceuticals Inc. (NASDAQ:FENC) news was published by Nasdaq.com which published an article titled: “Fennec Announces Publication of Pedmark(TM) Siopel 6 Clinical Data in the New England Journal of Medicine” on June 21, 2018.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.